Elena Stolyarova 1 , Liubov Beduleva 1 , Igor Menshikov 1 , Alexandr Snigiryev 2 , Tatyana Khramova 1 . Show Affiliations »
Abstract
BACKGROUND: One mechanism that underlies protection from autoimmunity and avoidance of uncontrolled inflammation is the controlled contraction of lymphocyte expansion during the immune response. We identified regulatory rheumatoid factor (regRF), the production of which is associated with resistance to and remission of experimental autoimmune diseases. RegRF is anti-idiotypic antibodies to lymphocyte receptors against autoimmune disease-inducing antigens; at the same time, it is specific to epitopes in the hinge Fc fragments of IgG. OBJECTIVE: The aim of this study is to test the hypothesis that regRF prevents autoimmunity by limiting the expansion of lymphocytes. METHODS: To test this hypothesis, we used a model of experimental autoimmune encephalitis. RESULTS: We found that in the lymph nodes that drain the injection site in rats producing regRF in response to immunization with myelin basic protein (MBP) the proportion of CD4+lymphocytes was lower than in rats in which MBP-immunization did not induce higher regRF levels. RegRF-containing plasma obtained from MBP-immunized rats induces complement-dependent killing of MBP-activated lymphocytes. Activated MBP-specific lymphocytes are not sensitive to the regRF-containing plasma of intact rats. CONCLUSION: The regRF produced during the immune response is a specific control factor for the expansion of antigen-activated CD4+lymphocytes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: One mechanism that underlies protection from autoimmunity and avoidance of uncontrolled inflammation is the controlled contraction of lymphocyte expansion during the immune response. We identified regulatory rheumatoid factor (regRF), the production of which is associated with resistance to and remission of experimental autoimmune diseases . RegRF is anti-idiotypic antibodies to lymphocyte receptors against autoimmune disease -inducing antigens; at the same time, it is specific to epitopes in the hinge Fc fragments of IgG. OBJECTIVE: The aim of this study is to test the hypothesis that regRF prevents autoimmunity by limiting the expansion of lymphocytes. METHODS: To test this hypothesis, we used a model of experimental autoimmune encephalitis . RESULTS: We found that in the lymph nodes that drain the injection site in rats producing regRF in response to immunization with myelin basic protein (MBP ) the proportion of CD4+lymphocytes was lower than in rats in which MBP -immunization did not induce higher regRF levels. RegRF-containing plasma obtained from MBP -immunized rats induces complement-dependent killing of MBP -activated lymphocytes. Activated MBP -specific lymphocytes are not sensitive to the regRF-containing plasma of intact rats . CONCLUSION: The regRF produced during the immune response is a specific control factor for the expansion of antigen-activated CD4+lymphocytes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Disease
Gene
Species
Keywords:
CD4+CD95+ lymphocytes; Experimental autoimmune encephalomyelitis; activated CD4+zzm321990lymphocytes; complement-dependent lysis; controlled contraction of lymphocyte expansion; regulatory rheumatoid factor.
Mesh: See more »
Substances: See more »
Year: 2018
PMID: 29521254 DOI: 10.2174/1871530318666180308123350
Source DB: PubMed Journal: Endocr Metab Immune Disord Drug Targets ISSN: 1871-5303 Impact factor: 2.895